- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04271332
Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion
An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 Deletion
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will enroll male or female subjects, aged 5 to 17 years, who have the 16p11.2 bp4-bp5 deletion. Subjects will be randomized to treatment with either placebo or arbaclofen. Subjects and study staff will be blinded to treatment assignment throughout the study. Both placebo and arbaclofen will be administered as orally disintegrating tablets. Dosing will be flexible, with subjects titrating up to the highest tolerated dose, with maximum permissible dose dependent on age. The treatment period is 16 weeks, after which subjects will taper off of study drug. Subjects will be required to attend multiple study visits, and to communicate with the study staff by phone multiple times throughout the study.
The primary efficacy assessment focuses on speech. Secondary and exploratory endpoints assess motor, memory, general cognitive, and other neuropsychological abilities, and brain electrophysiology. The safety evaluations include blood tests, physical exam, and assessment of adverse events.
Subjects who complete study participation through the end of the Withdrawal Period may be eligible to enroll in a subsequent open-label study. Dosing will be flexible, with subjects titrating up to the highest tolerated dose, with maximum permissible dose dependent on age. The treatment period is 16 weeks, after which subjects will taper off arbaclofen.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 15031
- Recruiting
- Boston Children's Hospital
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- New York State Psychiatric Institute (NYSPI)
-
Contact:
- Alyssa Verdes
- Phone Number: 914-997-5532
- Email: Alyssa.Verdes@nyspi.columbia.edu
-
Contact:
- Suvekcha Bhattachan
- Phone Number: 914-997-5532
- Email: suvekcha.bhattachan@nyspi.columbia.edu
-
-
Texas
-
Houston, Texas, United States, 77054
- Recruiting
- Texas Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98915
- Recruiting
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:To be eligible to participate in this study, all of the following criteria must be met:
- Diagnosis of 16p11.2 BP4-BP5 deletion.
- Male or female subjects, 5 through 17 years of age, at Screening.
- Neurodevelopmental disability requiring current educational or other therapeutic support.
- Any educational, behavioral, other therapeutic, and/or dietary interventions must have been continuous during the 2 months prior to Screening (with the exception of the anti-epileptic drug (AED) 6-month requirement in Inclusion Criterion #5). Subjects and their parent/caregiver/legally authorized representative (LAR) may not electively initiate new, or modify ongoing, interventions for the duration of the study. Typical school vacations are not considered modifications of stable programming.
- Subjects with a history of seizure disorder must have been seizure-free and on a stable antiepileptic therapy regimen for 6 months OR must have been seizure-free for the 3 years prior to Screening if not currently receiving antiepileptics. If currently receiving treatment with antiepileptics that are typically monitored by serum concentration, serum concentrations of the antiepileptic drugs must be tested and confirmed to be within the therapeutic range at Screening.
- All medication regimens must be stable for 30 days prior to Screening.
- Prior to the conduct of any study-specific procedures, the subject must provide assent to participate in the study (if developmentally appropriate), and the parent/caregiver/LAR must provide written informed consent. If the caregiver attending the clinic visits is not the parent or LAR, written consent must also be obtained from the parent or LAR for the subject's participation in the study.
- The subject's parent/caregiver/LAR must be able to speak and understand English sufficiently to understand the nature of the study and to allow for the completion of all study assessments. The parent/caregiver/LAR should be capable of providing reliable information about the subject's condition, agree to oversee the administration of the study drug, and accompany the subject to all clinic visits. The same parent/caregiver/LAR should accompany the subject to each visit.
- Negative pregnancy test for females who are 9 years of age or older. Both male and female subjects who are sexually active must agree to consistently use an accepted form of contraception (i.e., surgical sterilization, intrauterine contraceptive device, subcutaneous implant, oral contraceptive, or diaphragm or condom in combination with contraceptive cream/jelly, or abstinence) throughout the trial and for 30 days (females) or 90 days (males) following last study drug administration.
Exclusion Criteria:Subjects are not permitted to enroll in the study if any of the following criteria are met:
- Subjects with additional known genetic disorder besides 16p11.2 BP4-BP5 deletion.
- Subjects receiving remote or hybrid schooling at Screening.
- Subjects with an additional neurologic or psychiatric condition that might confound performance on assessments measures, e.g., significant impairment in hearing or vision, severe motor impairment (e.g., non-ambulatory) from cerebral palsy, birth injury, or other injury, or cleft lip or palate (including submucous cleft).
- Subjects with any seizures within the previous 6 months; subjects who are not currently receiving antiepileptics AND have had one or more seizures during the 3 years prior to Screening; and subjects who are shown to have non-therapeutic AED levels at Screening.
- Subjects with any medical or psychiatric condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to substance use disorders, impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular, respiratory, hepatic, or gastrointestinal disease.
- Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
- Subjects who are currently treated or have been treated with racemic baclofen in the last 30 days.
- Subjects currently treated with antipsychotic medication(s).
- Subjects currently treated with more than 2 psychoactive medications, including antiepileptics used as an anti-seizure treatment, but not including sleep aids used on an as-needed basis.
- Subjects currently treated with drugs having anxiolytic properties, including but not limited to: buspirone and beta-blockers. Benzodiazepines administered on a regular schedule (more than 3x/week) are not permitted. Use of antidepressants may be permitted with approval of the Medical Monitor. Other prohibited and restricted medications are shown in Appendix A.
- Subjects currently treated with vigabatrin, tiagabine, or riluzole.
- Subjects taking another investigational drug currently or within the last 30 days.
- Subjects who are not able or willing to take oral disintegrating tablets.
- Subjects who have a history of hypersensitivity to racemic baclofen.
- Subjects who, in the Investigator's opinion, might not be suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arbaclofen
Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
|
Arbaclofen tablet
Other Names:
|
Placebo Comparator: Placebo
The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
|
Manufactured to match Arbaclofen in size, shape, color and taste
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Goldman-Fristoe Test of Articulation, 3rd edition (GFTA-3), Sounds-in-Words
Time Frame: 12 weeks
|
The GFTA-3 is the most widely used, standardized test of articulation for children and adolescents.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wide Range Assessment of Memory and Learning - 2nd edition (WRAML2)
Time Frame: 12 weeks
|
The WRAML2 is a standardized test that measures memory functioning.
|
12 weeks
|
Bruininks-Oseretsky Test - 2nd edition (BOT-2), Fine Motor Control and Body Coordination subtests
Time Frame: 12 weeks
|
The BOT-2 is an individually administered, comprehensive measure of gross and fine motor skills.
|
12 weeks
|
Differential Ability Scale, 2nd edition (DAS-II)
Time Frame: 12 weeks
|
The DAS-II is an individually-administered clinical instrument for assessing the cognitive abilities that are important to learning.
|
12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRA16p201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on 16P11.2 Deletion Syndrome
-
Simons SearchlightBoston Children's Hospital; Geisinger Clinic; Simons FoundationRecruitingSMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditionsUnited States
-
Washington University School of MedicineDickson, Patricia I., M.D.; Milbrandt, Jeffrey, MD, PhD; Mitra, Rob, PhD; Turner...RecruitingChromosome 9P Deletion Syndrome | 9p Minus Syndrome | Alfi Syndrome | 9P Monosomy | 9P Partial Monosomy SyndromeUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)CompletedPhelan-McDermid Syndrome | 22q13 Deletion SyndromeUnited States
-
Centre Hospitalier Universitaire de NīmesCompleted22q11 Deletion Syndrome Di George SyndromeFrance
-
The Champ FoundationChildren's Hospital of Philadelphia; The Cleveland ClinicRecruitingPearson Syndrome | Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)United States
-
UMC UtrechtChildren's Hospital of Philadelphia; Netherlands Brain FoundationUnknownChromosome 22q11.2 Deletion SyndromeUnited States, Netherlands
-
Stephan EliezRecruitingtACS | 22Q11 Deletion SyndromeSwitzerland
-
Zynerba Pharmaceuticals, Inc.Completed22Q Deletion SyndromeUnited States, Australia
-
Innovation Research & TrainingRecruiting
-
Hôpital le VinatierRecruiting
Clinical Trials on Arbaclofen
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCWithdrawnMultiple Sclerosis | SpermUnited States
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCCompletedMultiple Sclerosis | SpasticityUnited States, Russian Federation, Ukraine
-
Evdokia AnagnostouMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsActive, not recruitingAutism Spectrum DisorderCanada
-
Seaside Therapeutics, Inc.TerminatedFragile X SyndromeUnited States
-
Seaside Therapeutics, Inc.TerminatedAutism Spectrum DisordersUnited States
-
Seaside Therapeutics, Inc.CompletedOpen-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum DisordersAutism Spectrum DisordersUnited States
-
Timothy RobertsSimons Foundation; Clinical Research Associates, LLCCompleted
-
Seaside Therapeutics, Inc.CompletedFragile X SyndromeUnited States
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCCompletedMultiple Sclerosis | Spasticity, MuscleSerbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
-
Seaside Therapeutics, Inc.CompletedFragile X SyndromeUnited States